Comparative Pharmacology
Head-to-head clinical analysis: ACYCLOVIR versus HERNEXEOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACYCLOVIR versus HERNEXEOS.
ACYCLOVIR vs HERNEXEOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.
Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (ADC). The antibody binds to HER2 on tumor cells, leading to internalization and intracellular release of the topoisomerase I inhibitor payload (DXd), which causes DNA damage and apoptosis.
400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.
2.5 mg subcutaneously once daily.
None Documented
None Documented
Clinical Note
moderateAcyclovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Acyclovir."
Clinical Note
moderateTizanidine + Acyclovir
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Terminal elimination half-life is 2.5–3.3 hours in adults with normal renal function; increases to 19.5 hours in anuria.
Terminal elimination half-life: 12 hours; clinical context: allows twice-daily dosing in most patients; renal impairment prolongs half-life up to 24 hours
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 62-90% of elimination. Fecal elimination is <2%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other routes
Category A/B
Category C
Antiviral
Antiviral